Management of acute bacterial skin and skin structure infections in India: are we equipped to meet the challenges of the growing menace of methicillin-resistant Staphylococcus aureus?


  • Chandrashekhar Mahakalkar Department of Surgery, Datta Meghe Institute of Medical Sciences, Jawaharlal Nehru Medical College, Wardha, Maharashtra, India
  • Devdatta Padhye Department of Surgery, Life point multi-speciality hospital, Pune, Maharashtra, India
  • Vishal R. Nandagawali Department of Surgery, Indira Gandhi Government Medical College and Hospital, Nagpur, Maharashtra, India
  • Shekhar Takale Department of Surgery, Oyster and Pearl Hospital, Pune, Maharashtra, India
  • Jaishid Ahdal Department of Medical Affairs, Wockhardt Limited, Mumbai, Maharashtra, India
  • Rishi Jain Department of Medical Affairs, Wockhardt Limited, Mumbai, Maharashtra, India



Acute bacterial skin and skin structure infections, Methicillin-resistant Staphylococcus aureus, Anti-MRSA agents, Multi-drug resistance


Staphylococcus aureus (S. aureus) is a Gram-positive facultative anaerobic bacterium that colonizes the skin and nasal passages of humans. The incidence of invasive S. aureus infections has increased over the past decades and is associated with poor outcomes and high mortality rates. S. aureus is responsible for almost one-third of acute bacterial skin and skin structure infections with methicillin-resistant Staphylococcus aureus (MRSA) accounting for a large proportion of these. The S. aureus strains prevalent inIndia are more aggressive and there are recent reports of the emergence of the more virulent multidrug resistant lineages ST2371 and ST8. Management of these infections is complicated by the fact that antimicrobial stewardship is non-existent, the choice of treatment is often empirical and available treatment options are limited due to a high prevalence of resistance strains. Currently available anti-MRSA agents include vancomycin, teicoplanin, linezolid, daptomycin, tigecycline, and clindamycin. However, the emergence of resistant strains and several undesirable features related to the safety and tolerability of these agents have limited the options available for the management of MRSA infections. A newer, safe and efficacious antibiotic is thus an unmet need for the management of MRSA in patients with acute bacterial skin and skin structure infections. In this review we explore the current and future trends in the management of acute bacterial skin and skin structure infections highlighting the challenges in their management in India, and current progress in the development of some novel drugs for the management of MRSA infections.


Esposito S, Bassetti M, Concia E, Simone DG, Rosa FG, Grossi P, et al. Diagnosis and management of skin and soft-tissue infections (SSTI) a literature review and consensus statement: an update. J Chemother. 2017;29(4):197-214.

Rodrigues MV, Fortaleza CM, Riboli DF, Rocha RS, Rocha C, Cunha ML, et al. Molecular epidemiology of methicillin - resistant Staphylococcus aureus in a burn unit from Brazil. Burns. 2013;39:1242-9.

Pollack CV, Amin A, Ford WT, Finley R, Kaye KS, Nguyen HH, et al. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015;48:508-19.

Ray SM. Preventing methicillin-resistant Staphylococcus aureus (MRSA) disease in urban US hospitals now for the hard part: more evidence pointing to the community as the source of MRSA acquisition. J Infect Dis. 2017;215:1631-3.

Rajkumar S, Sistla S, Manoharan M, Sugumar M, Nagasundaram N, Parija SC, et al. Prevalence and genetic mechanisms of antimicrobial resistance in Staphylococcus species: a multicentre report of the Indian council of medical research antimicrobial resistance surveillance network. Indian J Med Microbiol. 2017;35:53-60.

Joshi S, Ray P, Manchanda V, Bajaj J, Chitnis D, Gautam V, Goswami P, et al. Methicillin resistant Staphylococcus aureus (MRSA) in India: prevalence and susceptibility pattern. Indian J Med Res. 2013;137:363.

Nagaraju U, Raju BP. Methicillin-resistant Staphylococcus aureus in community-acquired pyoderma in children in South India. Indian J Paediatr Dermatol. 2017;18:14-7.

Hsiao CH, Chuang CC, Tan HY, Ma DH, Lin KK, Chang CJ, et al. Methicillin-resistant Staphylococcus aureus ocular infection: a 10-year hospital-based study. Ophthalmol. 2012;119:522-7.

Schmitz GR, Bruner D, Pitotti R, Olderog C, Livengood T, Williams J, et al. Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection. Ann Emerg Med. 2010;56:283-7.

Baig S, Johannesen TB, Petersen S, Larsen J, Larsen AR, Stegger M. Novel SCCmec type XIII (9A) identified in an ST152 methicillin-resistant Staphylococcus aureus. Infect Genetics Evol. 2018:1;61:74-6.

Nagasundaram N, Sistla S. Existence of multiple SCCmec elements in clinical isolates of methicillin-resistant Staphylococcus aureus. J Med Microbiol. 2019;1768(5):720-7.

Bergal A, Loucif L, Benouareth DE, Bentorki AA, Abat C, Rolain JM. Molecular epidemiology and distribution of serotypes, genotypes, and antibiotic resistance genes of Streptococcus agalactiae clinical isolates from guelma, Algeria and Marseille, France. Eur J Clin Microbiol Infect Dis. 2015;34:2339-48.

Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. Antimicrobial resistance: Not community- associated methicillin -resistant Staphylococcus aureus (CA-MRSA)! a clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis. 2011;52:99-114.

Boswihi SS, Udo EE, Monecke S, Mathew B, Noronha B, Verghese T, Tappa SB. Emerging variants of methicillin-resistant Staphylococcus aureus genotypes in Kuwait hospitals. PloS one. 2018;13(4):e0195933.

Nadig S, Raju SR, Arakere G. Epidemic meticillin-resistant Staphylococcus aureus (EMRSA-15) variants detected in healthy and diseased individuals in India. J Med Microbiol. 2010;59(7):815-21.

Falcone M, Concia E, Giusti M, Mazzone A, Santini C, Stefani S, et al. Acute bacterial skin and skin structure infections in internal medicine wards: Old and new drugs. Intern Emerg Med. 2016;11:637-48.

Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T, et al. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents. 2012;39:96-104.

Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:18-55.

Tee C. MRSA: Challenges and Updates; 2015. Available at Accessed on 3 January 2019.

Martin JH, Norris R, Barras M, Roberts J, Morris R, Doogue M, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Clin Biochem Rev. 2010;31:21-4.

Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:10-52.

Sartelli M, Malangoni MA, May AK, Viale P, Kao LS, Catena F, et al. World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections. World J Emerg Surg. 2014;9:57.

Berger A, Oster G, Edelsberg J, Huang X, Weber DJ. Initial treatment failure in patients with complicated skin and skin structure infections. Surg Infect. 2013;14:304-12.

Rodríguez MC, Castro AV, Ledo VL, Veleiro NI, Quintela GA. Skin and soft-tissue infections: Factors associated with mortality and re-admissions. Enferm Infect Microbiol Clin. 2017;35:76-81.

Mcginnis E, Cammarata S, Tan RD, Barrett M, Tuttle E. Characteristics of patients hospitalized for acute bacterial skin and skin structure infections (ABSSSI) from 2009 to 2013. Open Forum Infect Dis. 2016;3(1):279.

Dryden M, Andrasevic AT, Bassetti M, Bouza E, Chastre J, Cornaglia G, et al. A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: Current clinical opinion and practice. Clin Microbiol Infect. 2010;16(1):3-10.

Dryden M, Baguneid M, Eckmann C, Corman S, Stephens J, Solem C, et al. Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: Focus on skin and soft-tissue infections. Clin Microbiol Infect. 2015;21(2):27-32.

Suaya JA, Eisenberg DF, Fang C, Miller LG. Skin and soft tissue infections and associated complications among commercially insured patients aged 0-64 years with and without diabetes in the U.S. PLoS One. 2013;8:60057.

Lee BY, Singh A, David MZ, Bartsch SM, Slayton RB, Huang SS, et al. The economic burden of community- associated methicillin-resistant Staphylococcus aureus (CA - MRSA). Clin Microbiol Infect. 2013;19:528-36.

Methicillin resistant Staphylococcus aureus. Available at Accessed on 26 December 2019.

Scharff RL. Health-related costs from foodborne illness in the United States; 2010. Available at Accessed on 1 October 2019.

Labreche MJ, Lee GC, Attridge RT, Mortensen EM, Koeller J, Du LC, et al. Treatment failure and costs in patients with methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections: A South Texas ambulatory research network (STARNet) study. J Am Board Fam Med. 2013;26:508-17.

US Food and Drug Administration. Center for drug evaluation and research. guidance for industry. acute bacterial skin and skin structure infections: Developing drugs for treatment. Draft Guidance. Clinical/antimicrobial revision. Food and Drug Administration, Center for Drug Evaluation and Research; 2010. Available at Accessed on 21 December 2018.

Moellering RC. Discovering new antimicrobial agents. Int J Antimicrob Agents. 2011;37:2-9.

Vuong C, Yeh AJ, Cheung GY, Otto M. Investigational drugs to treat methicillin-resistant Staphylococcus aureus. Expert Opin Investig Drugs. 2016;25:73-93.

Antonoplis A, Zang X, Huttner MA, Chong KK, Lee YB, Co JY, et al. A dual-function antibiotic-transporter conjugate exhibits superior activity in sterilizing MRSA biofilms and killing persister cells. J Am Chem Soc. 2018;140:16140-51.

Skov RO, Frimodt MNI, Espersen FR. In vitro susceptibility of Staphylococcus aureus towards amoxycillin‐clavulanic acid, penicillin‐clavulanic acid, dicloxacillin and cefuroxime. Apmis. 2002;110(7‐8):559-64.

Bhagwat SS, Nandanwar M, Kansagara A, Patel A, Takalkar S. Levonadifloxacin, a novel broad-spectrum anti-mrsa benzoquinolizine quinolone agent: review of current evidence. Drug Des Devel Ther. 2019;13:4351-65.

Tellis M, Joseph J, Khande H, Bhagwat S, Patel M. In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin-and quinolone-resistant Staphylococcus aureus biofilms. J Med Microbiol. 2019;26:1-8.

Rodvold KA, Gotfried MH, Chugh R. Intrapulmonary pharmacokinetics of levonadifloxacin following oral administration of alalevonadifloxacin to healthy adult subjects. Antimicrob Agents Chemother. 2018;62(3):02297-17.






Review Articles